$Northwest Biotherapeutics(NWBO.US)$ Long-Term Survival: The “long tail” of the survival curve showed that more than double the patients survived longer than those treated with the standard of care, highlighting the potential for long-term benefits.
Safety Profile: DCVax-L exhibited a benign safety profile, with adverse events not meaningfully different from the standard of care. This is particularly important as it means the therapy can be administered with fewer concerns about severe side eff...

$Northwest Biotherapeutics(NWBO.US)$ Northwest Biotherapeutics Inc. (NWBO) is making progress towards regulatory approval for its DCVax®-L treatment for glioblastoma. They have submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. This submission is a significant step, but it indicates that approval is still pending

$Northwest Biotherapeutics(NWBO.US)$ Northwest Biotherapeutics Inc. (NWBO) has been involved in significant legal actions related to allegations of stock manipulation. The company has accused several defendants, including Citadel Securities, associated with Ken Griffin, of “spoofing” to manipulate NWBO’s stock price between 2017 and 2022. Spoofing involves placing orders to create the illusion of demand or supply, thus affecting the stock price and harming NWBO’s valuation. Ken Griffin and Citad...

$Northwest Biotherapeutics(NWBO.US)$ Northwest Biotherapeutics Inc. (NWBO) has made several significant moves recently. The company secured an exclusive license for advanced dendritic cell technologies from Roswell Park Comprehensive Cancer Center. This includes five new patent families with technologies currently in Phase 2 clinical trials for two cancers, and a third Phase 2 trial pending. This development aligns with NWBO’s strategy to enhance its portfolio and advance personalized immune the...

$Northwest Biotherapeutics(NWBO.US)$ Diamond hands

$Northwest Biotherapeutics(NWBO.US)$ Patent Coverage: NWBO has secured broad patent coverage for their manufacturing system and DCVax technology, protecting their innovations and potentially increasing their competitive advantage in the market

$Northwest Biotherapeutics(NWBO.US)$ Flaskworks System Development: The company has developed a new, automated manufacturing system called Flaskworks. This system aims to reduce production costs and increase scalability for DCVax-L. By transitioning from a manual to an automated process, NWBO expects to achieve higher efficiency and lower operational costs, which can positively impact profitability and production capacity

$Northwest Biotherapeutics(NWBO.US)$ Regulatory Submissions: NWBO has submitted a Marketing Authorization Application to the UK’s MHRA for DCVax®-L, aiming for approval to commercialize their treatment. Success in this regulatory step could open up significant market opportunities and provide a strong validation of their technology

$Northwest Biotherapeutics(NWBO.US)$  Phase III Trial Results for DCVax®-L: NWBO has reported positive top-line results from its Phase III trial for DCVax®-L in treating glioblastoma, a highly aggressive form of brain cancer. This trial showed meaningful survival extensions in patients, particularly in the “long tail” of the survival curve, with significantly better outcomes than standard treatments. These results were published in the peer-reviewed journal JAMA Oncology, enhancing credibility a...

$Chewy(CHWY.US)$ For some reason, Im smelling a possible short squeeze in chewy.
High shorts interest
Chewy has a strong foundation in financial health and management
Good news popping off from chewy
If anyone could correct me about any mistakes in my observation, pls comment Thank you